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Streptococcus pneumonia is the dominant pathogen of
community-acquired pneumonia, particularly in chil-
dren.1,2 Its serotypes are also associated with disease
severity.3,4 Shen and colleagues5 reported a 10-year study,
analyzing the relationship between serotypes and compli-
cations of invasive pneumococcal infection among pediatric
patients in Taiwan. In this article, several points require
further clarification. First, over 20% of patients in this study
had underlying medical conditions, including malignancy,
hematological disorders, genetic disorders, and other sys-
temic illness. Although the number of patients with prior
medical conditions were similar between groups, it was not
discussed whether these children’s disease status and prior
medical treatment records had been taken into account for
the analysis. For example, a child with new-onset acute
lymphocytic leukemia might have a much higher chance of
developing invasive pneumococcal infection, compared
with a child with glucose-6-phosphate dehydrogenase
deficiency but without a significant medical history. Unless
the physical status of these patients is similar, it is difficult
to determine whether serotype 3 is more virulent than the
others in this particular cohort. Second, this study included
three children who had previously received polysaccharide
pneumococcal vaccines. Because these children might
preserve immune protection induced by prior vaccination,
the virulence of certain vaccine serotypes might be
underestimated. Finally, the description of total number
was slightly unclear in several categories in Table 1. For
instance, the overall number of patients in “requirement of
ICU stay” was changed from 75 to 70 in case of 7-valent
pneumococcal vaccine serotypes, and from 30 to 29 in
case of non-7-valent pneumococcal vaccine serotypes.
These changes need to be explained in detail. Apart fromConflicts of interest: The author has no conflicts of interest
relevant to this article.
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0929-6646/Copyright ª 2015, Elsevier Taiwan LLC & Formosan Medicathe issues raised above, this article addressed the impor-
tance to monitor the shift of leading epidemic serotypes of
Streptococcus. The virulence of emerging serotypes should
be more closely monitored in the postvaccine era.
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